Effect of synuclein-gamma on malignant progression in human prostate cancer

Abstract

Objective To study the expression and significance of synuclein-gamma (SNCG) in human prostate cancer.Methods SNCG expression in the prostate epithelial cell line (RWPE-1) and the hormone-dependent prostate cancer cell lines (LNCaP,CWR22) was detected by using reverse transcriptase-polymerase chain reaction (RT-PCR) and Western blotting.The immunohistochemistry was performed to investigate the expression of SNCG in the normal prostate tissue,prostatitis tissue,benign prostatic hyperplasia (BPH) tissue,high-grade prostatic intraepithelial neoplasia,and hormone-dependent prostate cancer (HDPC) tissue.Results The expression of SNCG in hormone-dependent prostate cancer cell line was significantly higher than that in prostate epithelial cell line.Almost no SNCG was detectable in benign prostate specimens (10 normal prostate tissues,10 prostatitis tissues,and 10 BPH tissues),SNCG was partially expressed in high-grade prostatic intraepithelial neoplasia (3/10),and the expression was elevated to a high level in HDPC tissues (the positive rate 60.66％,74/122).Combined with the SNCG stain score and the clinicopathological parameters of the corrresponding PCa patients,we found that SNCG protein expression was associated with middle-high-risk PCa characterized by prostate specific antigen (PSA) ≥ 10 μg/L,Gleason score≥7,and clinical stage≥T2b,and correlated with lymph node metastasis.Conclusion These results suggested that abnormal expression of SNCG may be involved in malignant progression of PCa. Key words: Synuclein-gamma ; Prostate cancer; Immunohistochemistry